<DOC>
	<DOCNO>NCT00460720</DOCNO>
	<brief_summary>The survey design identify non-compliant Attention Deficit Hyperactivity Disorder ( ADHD ) patient currently Immediate- Released Methylphenidate ( IR-MPH ) observe change compliance treat drug intend treat ADHD 3 week</brief_summary>
	<brief_title>Compliance Survey ADHD Medication Optimal Satisfaction ( COSMOS )</brief_title>
	<detailed_description>This Observational , survey study . The survey design administer two stage . In first stage , patient prescribe Immediate-Released Methylphenidate ( IR-MPH ) 3 month , also IR-MPH 1 month prior meet inclusion criterion enrol . On survey day 1 , patient , parents/caregivers , clinician assess patient drug compliance . For patient consider non-compliant , Investigator decide whether change current medication . Those patient whose medication change IR-MPH another treatment ADHD , enrol second stage . On survey day 1 , Clinical Global Impression ( CGI ) effect medication sleep quality , decrease appetite , dizziness headache , gastrointestinal upset assess base clinical interview . Any side effect show medication treatment also record first stage . Parent/Caregivers need complete Swanson , Nolan Pelham ( SNAP ) Questionnaire evaluate ADHD child 's symptoms inattention , hyperactivity , impulsivity oppositional defiant disorder . In second stage , ADHD patient meet definition non-compliance treat medication three week . On first visit back start treatment medication , drug compliance , CGI , change negative parent-child interaction , overall classroom behavior , overall academic performance , effect sleep quality , decrease appetite , diziness headache , gastrointestinal upset assess Investigator interview . Parent/Caregivers need complete SNAP Questionaire evaluate ADHD child 's symptoms inattention , hyperactivity , impulsivity oppositional defiant disorder . It survey type study . No study drug use study .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients clinical diagnosis DSMIV ADHD Patients previously treat ImmediateReleased Methylphenidate ( IRMPH ) take day , twice day , three time day , four time day three month also IRMPH last month without severe adverse event possible contraindication MPH Patients whose parent guardian sign date informed consent participate survey drug compliance Patients still school ADHD patient systematic disease clinically significant gastrointestinal problem , include narrowing ( pathologic iatrogenic ) gastrointestinal tract ADHD patient also diagnose psychosis except Conduct Disorder Oppositional Defiant Disorder</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>ADHD</keyword>
	<keyword>Methylphenidate</keyword>
	<keyword>MPH</keyword>
	<keyword>Extended-Release Methylphenidate</keyword>
</DOC>